alexa OPERA and Phase III Trials for Testing the Hypothesis That Planned Organ Preservation is Feasible in Selected Rectal Cancers | Open Access Journals
Journal of Cancer Clinical Trials
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

OPERA and Phase III Trials for Testing the Hypothesis That Planned Organ Preservation is Feasible in Selected Rectal Cancers

JP Gérard*, K Benezery and J Doyen

Centre Antoine-LACASSAGNE, 33 Avenue de Valombrose, Nice-France

*Corresponding Author:
Jean-Pierre Gérard
Centre Antoine-LACASSAGNE
33 Avenue de Valombrose, Nice-France
E-mail: [email protected]

Received date: March 30, 2017; Accepted date: March 31, 2017; Published date: April 05, 2017

Citation: Gérard JP, Benezery K, Doyen J (2017) OPERA and Phase III Trials for Testing the Hypothesis That Planned Organ Preservation is Feasible in Selected Rectal Cancers. J Cancer Clin Trials 2: =e107.

Copyright: © 2017 Gérard JP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Cancer Clinical Trials

Editorial

Surgery is and will remain the major curative treatment for rectal cancer. Permanent stoma after abdomino-perineal resection (APR) is becoming unusual but even after low anterior resection (LAR) the quality of life is often poor due to bowel movement dysfunction. First line radiotherapy or chemoradiotherapy (CRT) is becoming a popular way of research to achieve clinical complete response (cCR) and organ preservation. Papillon [1] in the 1970s was one of the first to achieve cCR and long term local control using contact X ray brachytherapy (CXB) for T1N0 and Habr Gama [2] using CRT for T2-3 popularized in the 1990s watch and wait (W-W) after cCR. The Lyon R 90-01 randomized trial [3,4] demonstrated that a CXB boost combined with external beam radiotherapy (EBRT) was able for T2 T3 ≤ 4 cm distal rectum in operable patients to increase sphincter and organ preservation.

Presently the world reference for organ preservation is Habr Gama regimen with CRT: 54 Gy with capecitabine. Using this protocol for T2-3 tumor the rate of cCR is between 15 to 40% (depending on tumor size, stage and interval before response evaluation) and the rate of local relapse after W-W is around 25-30% [5-7]. Such an approach is considered as a good option in the ESMO guideline [8]. As rectal adenocarcinoma is quite a radioresistant tumor [9] combining CRT with a CXB boost is an attractive way of research to increase organ preservation. With this combined treatment results achieved in France and UK since 2002 [10-12] show a rate of cCR for T2 T3 <5 cm of ≥ 75% and local relapse in less than 15% of cases with good bowel function. Relapse in the perirectal nodes are <5%.

To demonstrate that a CXB boost is increasing safely the chance of organ preservation the European OPERA trial (ID-RCB 2014-A0 1851-46) was launched in June 2015. Main Inclusion criteria using mainly colonoscopy and MRI: Adenocarcinoma (well-moderately differentiated) T2 T3 a-b <5 cm, N0, M0 distal-middle rectum, operable patient. All the patients received CRT (45 Gy/5 weeks) with concurrent capecitabine (825 mg/ m2 BID). Randomization is between boost with either EBRT (9 Gy/1 week) or CXB (90 Gy/3 fractions). Tumor response (Digital examination, rectoscopy, MRI) is made on week 14 after start of treatment. If cCR is achieved surveillance or local excision is proposed. In case of partial response TME is performed. End point is organ preservation at 3 years and the hypothesis is to increase organ preservation from 20% to 40% in the CXB group (HR: 0.56). Inclusion of 236 patients should end in 2019 with patients from France, UK, Sweden and Switzerland.

Some other trials (Greccar 12, Star-Tec, Prospect) are testing the possibility to achieve organ preservation using CRT and neoadjuvant chemotherapy. A key point for success is the tumor selection. If large T3 (>4 cm, T3c-d) are included the chance of cCR with CRT alone is less than 15% [13]. On the other hand if T2 and “early” T3 are selected a CRT with CXB boost can achieve a high rate of long term local control and as in anal canal squamous cell carcinoma a planned organ preservation can be proposed to frail patients or if any TME surgery is refused. Long term surveillance is needed as it is possible to see local failure after 5 years which can still be salvaged. A rate of local failure below 15% is the goal if this conservative strategy is not to compromise survival.

As always only randomized trials will bring strong evidence that this combined treatment is providing good and safe organ preservation and could be considered not only as an option but as a standard.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 234
  • [From(publication date):
    May-2017 - Oct 17, 2017]
  • Breakdown by view type
  • HTML page views : 191
  • PDF downloads :43
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords